NovoCure Ltd Earnings Per Share Diluted

• NovoCure Ltd showed an increase of +21.8% in Earnings Per Share Diluted from 2024 to 2025.
• This data is from NovoCure Ltd's annual report (Form 10-K), filed with the SEC on February 26, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q3 2018: $0.13 (loss) per share | Q1 2019: $0.13 (loss) per share | Q2 2019: $0.01 (loss) per share | Q3 2019: $0.02 per share | Q4 2019: $0.04 per share | Q1 2020: $0.04 per share | Q2 2020: $0.02 per share | Q3 2020: $0.09 per share | Q4 2020: $0.04 per share | Q1 2021: $0.04 (loss) per share | Q2 2021: $0.14 (loss) per share | Q3 2021: $0.13 (loss) per share | Q4 2021: $0.25 (loss) per share | Q1 2022: $0.04 (loss) per share | Q2 2022: $0.23 (loss) per share | Q3 2022: $0.25 (loss) per share | Q4 2022: $0.36 (loss) per share | Q1 2023: $0.50 (loss) per share | Q2 2023: $0.54 (loss) per share | Q3 2023: $0.46 (loss) per share | Q1 2024: $0.36 (loss) per share | Q2 2024: $0.31 (loss) per share | Q3 2024: $0.28 (loss) per share | Q1 2025: $0.31 (loss) per share | Q2 2025: $0.36 (loss) per share | Q3 2025: $0.33 (loss) per share.
• Over the full 8 years of available data (2018 to 2025), NovoCure Ltd's Earnings Per Share Diluted has declined by 76.8%.
• Historical annual values: Fiscal year 2025: $1.22 (loss) per share | Fiscal year 2024: $1.56 (loss) per share | Fiscal year 2023: $1.95 (loss) per share | Fiscal year 2022: $0.88 (loss) per share | Fiscal year 2021: $0.56 (loss) per share | Fiscal year 2020: $0.18 per share | Fiscal year 2019: $0.07 (loss) per share | Fiscal year 2018: $0.69 (loss) per share.
• Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: August 6, 2026